Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Gross Margin · Q4 FY2026 · quarter ended Sep 2026

Gross margin narrows to 95.2%

Gross margin was 95.2% in Q4 FY2026, down 4.8 pp from a year earlier. On a trailing-twelve-month basis it was 99.6%, down 0.4 pp year over year. Over 3 fiscal years it widened by 4.8 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
95.2%-4.8 pp QoQ
Last fiscal yearSep 2026
99.6%-0.4 pp YoY
LTMSep 2026
99.6%-0.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-4.8 pp——
1 year-0.4 pp——
3 years+4.8 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2026
99.6%
Year-over-year change
-0.4pp

Gross Margin vs competitors

How ARWR compares with its peers on the latest reported figures

  • ARWR's LTM Sep 2026 gross margin of 99.6% is the highest of the 7 companies compared; the peer median is 90.5%.
  • Its year-over-year change of -0.4 pp is the highest of 6, against a peer median of -4.1 pp.
  • Over three fiscal years its change of +4.8 pp compares with a peer median of -3.2 pp.
ARWR Competitors Peer median
Gross Margin for ARWR and competitors
Company Period LTM level YoY 3-year change
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 202699.6% -0.4 pp+4.8 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 202698.2% -0.6 pp+0.7 pp
WVEWave Life Sciences Ltd.LTM Mar 202693.8% -4.1 pp-20.7 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 202691.2% -8.8 pp-4.5 pp
PRQRProQR Therapeutics N.V.LTM Mar 202689.7% -10.3 pp-17.0 pp
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202679.7% -3.9 pp-2.0 pp
SLNSilence Therapeutics plcLTM Mar 202666.4% —+23.7 pp
Peer median (excluding ARWR) 90.5%-4.1 pp-3.2 pp

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.